Tri-Conference 2008 | Molecular Diagnostics

会议将同时进行

1. Molecular Diagnostics 2. Mastering Medicinal Chemistry 3. Pathway Analysis 4. Stem Cells Congress 5. R&D Risk Mitigation 6. Clinical Trials Asia 7. Preclinical Development 8. Translational Medicine 9. Cytokine-Based Therapeutics 10. Cancer Molecular Markers 11. Trends in Drug Safety

媒体夥伴

Insight Pharma Reports产业/市场情报数据

Molecular Diagnostics

[ 概要 | 展销前置会 | 1日目 | 2日目 | 3日目 | Catalog(PDF) ]

Molecular Diagnostics

第5回分子诊断 - 个性化医疗中的合作伙伴
2008年3月26～28日

大会
开幕：专题演讲
在发展中国家的制品上市成功事例
在分子诊断(companion diagnostics)中的案例学习(case study) (研究开发的风险低减和癌的分子标靶之共同议程)
分子诊断的未来动向
癌的分子诊断(与癌的分子标靶之共同议程)

PLENARY KEYNOTE SPEAKERS

Diagnosing the Disease: Disruptive Innovation in Healthcare
Clayton M. Christensen, DBA, Robert and Jane Cizik Professor of Business Administration, Harvard Business School

Disruption of the Pharmaceutical Industry: Moving from Products to Solutions
Elizabeth L. Bewley, MBA, Vice President, Strategic Planning, Johnson & Johnson Health Care Systems Inc.

Risk Diagnosis for Disease Prevention
C. Thomas Caskey, M.D., F.A.C.P., Director and Chief Executive Officer, Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center

KEYNOTE SPEAKERS

Regulation of Diagnostic Tests
Steven I. Gutman, M.D., Director, Office of In Vitro Diagnostic Device Evaluation and Safety, Food & Drug Administration

Clinical Diagnostics and Imaging for Early Health
Christoph Hergersberg, Ph.D., Global Research Leader, Biosciences, GE Global Research Center

Prospective Medicine: The Next Health Care Transformation
Ralph Snyderman, M.D., Chancellor Emeritus & James B Duke Professor Medicine, Duke University and Proventys

LOC: The Next Generation Molecular Diagnostic Device
Christopher Ko, Ph.D., Chief Operations Officer, Bio Business Planning, Samsung Advanced Institute of Technology

Polymerase Chain Reaction: A Quarter Century of Pioneering Discovery and Promises for the Future
David H. Gelfand, Ph.D., Chief Scientific Officer, BioSystems

Organizational, Strategic and Technical Considerations for Creating Clinically Differentiated Medicines
Tim M. Jaeger, M.D., Ph.D., MBA, Head of Divisional Medical and Scientifi c Affairs, F. Hoffmann-La Roche Ltd., Diagnostics Division